ONCBeOne Medicines Ltd.
- BusinessWire
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 status Regimen poised to become ...
- BusinessWire
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 BeOne Medicines Ltd. ("BeOne") (NASDAQ:ONC, HKEX: ...
- BusinessWire
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers Regional rights agreement provides BeOne ...
- Analyst Upgrades
TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454
TD Cowen analyst Yaron Werber maintains BeOne Medicines with a Buy and raises the price target from $424 to $454. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450
RBC Capital analyst Leonid Timashev maintains BeOne Medicines with a Outperform and lowers the price target from $451 to $450. ...
- Analyst Upgrades
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418
Truist Securities analyst Gregory Renza maintains BeOne Medicines with a Buy and raises the price target from $416 to $418. ...
- Analyst Upgrades
Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430
Guggenheim analyst Michael Schmitz maintains BeOne Medicines with a Buy and raises the price target from $420 to $430. ...
- Analyst Upgrades
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405
Citizens analyst Reni J. Benjamin maintains BeOne Medicines with a Market Outperform and raises the price target from $396 to $405. ...
- BusinessWire
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year BRUKINSA (zanubrutinib) global revenues of $1.2 billion for the second quarter, an increase of 31% from the ...
- Analyst Upgrades
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425
JP Morgan analyst Jessica Fye maintains BeOne Medicines with a Overweight and raises the price target from $415 to $425. ...
- BusinessWire
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
$300 million expansion of flagship manufacturing facility in Hopewell, New Jersey, adds small molecule manufacturing capacity, enhancing U.S. domestic production capabilities Creates 120 new full-time jobs to support ...
- BusinessWire
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the financial markets open. Following ...
- Analyst Upgrades
Barclays Maintains Overweight on BeOne Medicines, Lowers Price Target to $403
Barclays analyst Peter Lawson maintains BeOne Medicines with a Overweight and lowers the price target from $409 to $403. ...
- Analyst Upgrades
Jefferies Upgrades BeOne Medicines to Buy, Raises Price Target to $380
Jefferies analyst Faisal Khurshid upgrades BeOne Medicines from Hold to Buy and raises the price target from $333 to $380. ...
- Analyst Upgrades
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $451
RBC Capital analyst Leonid Timashev maintains BeOne Medicines with a Outperform and raises the price target from $436 to $451. ...
- Analyst Upgrades
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $416
Truist Securities analyst Gregory Renza maintains BeOne Medicines with a Buy and raises the price target from $413 to $416. ...
- Analyst Upgrades
Citizens Reiterates Market Outperform on BeOne Medicines, Maintains $396 Price Target
Citizens analyst Reni J. Benjamin reiterates BeOne Medicines with a Market Outperform and maintains $396 price target. ...
- BusinessWire
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFS MANGROVE is the first Phase 3 ...
- BusinessWire
BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment BRUKINSA plus sonrotoclax (ZS) ...
- BusinessWire
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk features New European patient research reveals safety, disease severity, and ...
- Earnings Call Transcripts
Goldman Sachs 47th Annual Global Healthcare Conference - BeOne Medicines
All right. Thank you, everyone, for joining this session. My name is Ling Haizhang. I'm the China Biotech Analyst. Today, with great privilege, we have the opportunity to host the management from B1 Medicines. On the fur ...
- Analyst Upgrades
RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $436
RBC Capital analyst Leonid Timashev maintains BeOne Medicines with a Outperform and raises the price target from $425 to $436. ...
- BusinessWire
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development Company to host investor webcast showcasing momentum across ...
- BusinessWire
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy BRUKINSA plus next-generation BCL2 ...
- BusinessWire
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEA Oral presentation at ASCO highlights benefit ...